Overview
Spherix’s coverage of emerging dermatology indications focuses on evolving markets where a paradigm shift is expected in the coming years.
Services Available
Prepping for the pipeline
-
Alopecia Areata (US)
-
Alopecia Areata (EU)
-
Chronic Spontaneous Urticaria (US)
-
Hidradenitis Suppurativa (US)
-
Hidradenitis Suppurativa (EU)
-
Prurigo Nodularis (US)
-
Vitiligo (US)
Service Info
Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Methodology: Insights are based on analyses of quantitative data collected from an online survey of specialists, patients, and leading KOLs recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents and select KOLs.
Sample Size and Frequency
Annual report (n=100-200 physicians)
Qualitative interviews (n=6-8 physicians, n=2-3 KOLs)
Benchmarking new brand performance
-
Ligelizumab (Novartis) in Chronic Spontaneous Urticaria (US)*
-
Olumiant (Eli Lilly) in Alopecia Areata (US)*
-
Ritlecitinib (Pfizer) in Alopecia Areata (US)*
-
Ruxolitinib (Incyte) in Vitiligo (US)*
Service Info
Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Methodology: Insights are based on analyses of quantitative data collected from an online survey of physicians “in the trenches” recruited from the Spherix Network, as well as qualitative interviews conducted with a subset of survey respondents.
Sample Size and Frequency
Monthly KPI benchmarking (n=75 physicians)
Quarterly report (n=75 physicians)
Quarterly qualitative interviews (n=8 physicians)